ClinicalTrials.gg
Active, not recruitingNCT05487599Updated Aug 17, 2026

A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)

A Phase 1/2 interventional study of LY3884961 in Gaucher Disease and Gaucher Disease, Type 1, sponsored by Prevail Therapeutics. Active, not recruiting at 5 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by Prevail Therapeutics (part of Eli Lilly and Company) · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 92 studies in Gaucher Disease with a site in United States — 20 open to participants now, 27 under way, 2 of them phase 3. Gaucher Disease · United States.

Enrollment
42nd of 51
8 · median 30
Started
2022
with 4 others
Phase 1/2
6 of 92
none open now
Primary completion
2031-08
later than 21 of 25 live
Registered
78th of 92
by date

Among the 92 studies in Gaucher Disease with a site in United States, this one is the 42nd largest by enrollment of the 51 interventional ones that give a count, is one of 5 that started in 2022, is one of 6 in phase 1/2, reaches primary completion later than 21 of the 25 other live ones, and was the 78th registered.

Gaucher Disease

177 studies on the registry are indexed under Gaucher Disease; 41 are open to participants now.

Browse Gaucher Disease studies →

Open to participants now

20 of the 92 studies in Gaucher Disease with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 26 Gaucher Disease studies recruiting now, 11 (42%) set no upper age limit and 11 (42%) stop at 75 or younger; 15 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 92 studies in Gaucher Disease with a site in United States, or all of them as a file.
02

Study summary

Study J3Z-MC-OJAE is a Phase 1/2, multicenter, open-label, dose-finding study of LY3884961 evaluating the safety and tolerability in adults with peripheral manifestations of GD.

Up to 3 dose levels of LY3884961 will be assessed in 3 dose-finding cohorts of 3 patients. Following this, up to 6 patients may be enrolled in an expansion cohort.

For each enrolled patient, the study will be approximately 5 years in duration, including up to a 60-day screening period. During the first 18 months after dosing, subjects will be evaluated for the effects of LY3884961 on safety, tolerability, immunogenicity, biomarkers, and efficacy. Patients will be followed for an additional 42 months to monitor safety, immunogenicity, and selected biomarker and efficacy parameters.

03

Conditions studied

  • Gaucher Disease
  • Gaucher Disease, Type 1

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age greater or equal to 18 years at the time of .
  2. Bi-allelic pathogenic GBA1 variants must be centrally confirmed.
  3. On ERT or SRT for at least 2 years and on a stable, maximum tolerated dose, for at least 3 months prior to screening.
  4. Capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  5. Females and males will be eligible for this study. Men and women of must use a highly effective method of consistently and correctly for the duration of the study, including the long-term follow-up.
  6. Patients must agree to abstain from blood, tissue and organ donation; and must agree to abstain from tissue and organ donation for the duration of the study, including long-term follow-up.

Exclusion criteria

Exclusion Criteria:

  1. neurological signs and symptoms and/or behavioral disturbances.
  2. Active and progressive bone disease expected to require surgical treatment in the next 6 months.
  3. History of total splenectomy or planned total splenectomy during the first 18 months of the study. (Partial splenectomy not exclusionary).
  4. Splenomegaly > 10 MN as evaluated by centrally read abdominal magnetic resonance imaging (MRI)
  5. Evidence of clinically significant liver disease, fragile liver, or history of exposure to hepatotoxins.
  6. Thrombocytopenia with count \< 40 × 10\^3 per μL.
  7. Severe hyperlipidemia (triglycerides > 1,000 mg/dL).
  8. Current diagnosis of unstable or clinically significant cardiovascular conditions based on Investigator assessment.
  9. History of certain cancers within 5 years of Screening.
  10. Concomitant disease, condition or treatment which, in the opinion of the Investigator, would pose an unacceptable risk to the patient or interfere with the patient's ability to comply with study procedures or interfere with the conduct of the study.
  11. Women of , pregnant (i.e., positive serum pregnancy result at Screening and/or Check-in) or breastfeeding or intending to become pregnant during the course of the trial.
  12. Use of any GD-related chaperone therapy within 4 weeks prior to Screening or expected need to initiate chaperone therapy during at least the first 18 months of the study.
  13. Any type of prior gene or cell therapy.
  14. Use of systemic or therapy other than protocol-specified immunosuppression.
  15. Participation in another therapeutic drug or device study within 3 months or 5 half-lives of the study agent, whichever is longer.
  16. Have an anti-AAV9 antibody titer of >1:40 as determined by central laboratory.
  17. Clinically significant abnormalities in laboratory test results at Screening.
  18. Have any for MRI, including claustrophobia or the presence of contraindicated metal (ferromagnetic)implants/cardiac pacemaker.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    LY3884961

    LY3884961 is an advanced therapy investigational medicinal product administered as a single intravenous infusion.

    Genetic: LY3884961

Interventions

  • GeneticLY3884961

    • LY3884961 is a replication-incompetent recombinant adeno-associated virus (AAV) vector. The vector is composed of a ss DNA genome packaged in an AAV-derived protein capsid.

06

What researchers measure

Primary outcomes

  1. Incidence and severity of Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) with AE's graded as mild, moderate, or severe.

    Time frame: 5 years

Secondary outcomes

  1. Spleen volume

    Change and percent change from baseline

    Time frame: 5 years

  2. Platelet count

    Change from baseline

    Time frame: 5 years

  3. GCase levels

    Change from baseline

    Time frame: 5 years

  4. GlcSph levels

    Change from baseline

    Time frame: 5 years

  5. Discontinuation of enzyme replacement therapy (ERT)/substrate reduction therapy (SRT)

    Time from dosing to discontinuation of ERT/SRT

    Time frame: 5 years

  6. Re-initiation of ERT/SRT (if necessary)

    Time to development of criteria requiring re-initiation of ERT/SRT (if necessary)

    Time frame: 5 years

07

Study locations

5 sites
  • Duke University Health System
    Durham, North Carolina 27710-3017, United States
  • Lysosomal & Rare Disorders Research and Treatment Center
    Fairfax, Virginia 22030-6066, United States
  • Westmead Hospital-Cnr Hawkesbury and Darcy Rds
    Westmead, New South Wales 2145, Australia
  • SphinCS Clinical Science for LSD
    Höchheim, 65239, Germany
  • Hospital Quironsalud Zaragoza, Paseo Mariano Renovales Sn
    Zaragoza, 50006, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2022 (actual). Primary completion is estimated for Aug 2031, 104 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2022
First posted
Aug 4, 2022
StartActual
Dec 20, 2022
Primary completionEst.
Aug 30, 2031
CompletionEst.
Aug 30, 2031
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05487599
Responsible party
Sponsor
First posted
Aug 4, 2022
Start date
Dec 20, 2022
Primary completion
Aug 30, 2031 (estimated)
Completion
Aug 30, 2031 (estimated)
Last update
Aug 17, 2026

Study contacts

Aaron Tward, MD, PhD
study director · Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion